Summarized by Masters of Longevity from Longevity Docs News.
Two 52-week trials found orforglipron lowered AHI versus placebo in adults with obesity.
Key Takeaways
- Orforglipron reduced AHI by about thirteen events per hour.
- Hypoxic burden and inflammation measures were improved with orforglipron.
- Gastrointestinal side effects were common and raised discontinuation rates.
